BioCryst Pharmaceuticals, Inc.

As of June 30, 2026, BioCryst Pharmaceuticals, Inc. carries a market capitalization of 44.67B, placing it among publicly traded companies globally. Its enterprise value stands at 52.37B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

BioCryst Pharmaceuticals, Inc.'s next confirmed earnings release is scheduled for November 4, 2026.

As of June 30, 2026, BioCryst Pharmaceuticals, Inc. has 255.27M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 2.44, and the price-to-book ratio stands at -5.63.

These figures are as of June 30, 2026. The EV/Sales ratio of 3.19 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 52.37B versus a market cap of 44.67B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, BioCryst Pharmaceuticals, Inc. maintains a current ratio of 2.32, meaning it holds 2.3x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is -174.52, indicating conservative leverage, while an interest coverage ratio of -4.14 demonstrates limited ability to service its debt obligations.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -75.79, reflecting losses generated across the asset base. The company generates approximately 34.87M in revenue per employee across its workforce of 471.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 3.77 indicates how many times BioCryst Pharmaceuticals, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, BioCryst Pharmaceuticals, Inc. recorded 60.91M in income tax expense. The company reported a pretax loss of -6.66B and -6.72B in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 15, 2026, BioCryst Pharmaceuticals, Inc.'s stock has declined approximately 6.27% over the past 52 weeks. The 50-day moving average sits at 167.85, while the 200-day moving average is 225.02.

Over the twelve months ended June 30, 2026, BioCryst Pharmaceuticals, Inc. generated 16.43B in revenue and converted that into -6.72B in net income, yielding earnings per share of -28.40. EBITDA reached -5.44B, while operating income came in at -5.47B.

As of June 30, 2026, BioCryst Pharmaceuticals, Inc. holds 6.16B in cash and equivalents against 13.85B in total debt, resulting in a net debt position of 10.89B. Total book value stands at -7.94B, with working capital of 4.82B providing operational flexibility.

BioCryst Pharmaceuticals, Inc. produced 6.57B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -48.19M in capital expenditures, free cash flow totaled 6.52B - equivalent to 28.43 per share.

Over the twelve months ended June 30, 2026, BioCryst Pharmaceuticals, Inc. posted a gross margin of 97.78, reflecting its pricing power and cost economics. The operating margin of -33.29 and net profit margin of -40.90 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 15.75, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield is negative at -4.87, meaning BioCryst Pharmaceuticals, Inc. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, BioCryst Pharmaceuticals, Inc. has an Altman Z-Score of -3.45, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.